Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 112 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed No phase listed Observational Accepts healthy volunteers

Pulse Oximetry Performance Comparison in Newborns

NCT06637917
Conditions
Newborn, Birth, Preterm
Interventions
OxySoftN™ Neonatal-Adult SpO2 Sensor with N600X Nellcor™ Patient Monitoring System, LNCS® NEO SpO2 Sensor with RAD-97™ Pulse CO-Oximeter, 1041PTS (or similar) Kendall™ Neonatal Electrodes with IntelliVue MP5 Portable Patient Monitor
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
29 Weeks and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Los Angeles, California • St Louis, Missouri • Winston-Salem, North Carolina
Conditions
No Specific Medical Conditions or Disease States
Interventions
Telemetry monitoring
Device
Lead sponsor
Turtle Shell Technologies Pvt. Ltd.
Industry
Eligibility
22 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Lake Jackson, Texas
Conditions
Atrial Fibrillation, Cardiovascular Diseases, Heart Diseases, Arrhythmias, Cardiac, Pathologic Processes
Interventions
Insertable Cardiac Monitor or external non-invasive LT-ECG patch
Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, New York
Conditions
Breast Cancer, HER2-positive Breast Cancer, HER2-positive Metastatic Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage IV, Cardiotoxicity
Interventions
Cardiopulmonary Exercise Test, Echocardiogram, Echocardiography
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Hypertrophic Cardiomyopathy, Nonsustained Ventricular Tachycardia, Ventricular Tachycardia, Atrial Fibrillation, Arrhythmia
Interventions
Zio XT
Device
Lead sponsor
iRhythm Technologies, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Accepts healthy volunteers Results available

Validation Study: Extended Wear Performance of the Zio Monitor - SHASTA II

NCT07205367
Conditions
Cardiac Arrhythmia
Interventions
Zio Monitor
Device
Lead sponsor
iRhythm Technologies, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
San Francisco, California • Deerfield, Illinois
Conditions
Post-Operative Cancer Patients Experiencing Atrial, Fibrillation
Interventions
questionnaire about the use of ECG device
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
22 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Conditions
Hypertension
Interventions
Device under test evaluation against references
Device
Lead sponsor
Aktiia SA
Industry
Eligibility
22 Years to 59 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Broomfield, Colorado
Conditions
Atrial Fibrillation Paroxysmal, Atrial Fibrillation, Persistent, Cardiac Arrhythmia, Ablation
Interventions
Holter monitoring in patients who have been successfully implanted with an Abbott Assert-IQ ICM device
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 100 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
11
States / cities
San Diego, California • Orlando, Florida • Overland Park, Kansas + 8 more
Not listed Not applicable Interventional

Cryptogenic Stroke Study

NCT00861133
Conditions
Cryptogenic Stroke
Interventions
Sleuth AT Implantable ECG Monitoring System
Device
Lead sponsor
Transoma Medical
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Completed Not applicable Interventional Accepts healthy volunteers Results available

Implementation of Practice Standards for ECG Monitoring

NCT01269736
Conditions
Cardiovascular Disease
Interventions
Education
Behavioral
Lead sponsor
Yale University
Other
Eligibility
Not listed
Enrollment
92,057 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
14
States / cities
Long Beach, California • San Francisco, California • New Haven, Connecticut + 10 more
Conditions
Arrhythmias, Cardiac, Atrial Fibrillation, Atrial Flutter, Bradycardia, Tachycardia
Interventions
Vectorcardiography (VECG)
Device
Lead sponsor
HeartBeam, Inc.
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
5
States / cities
Atlanta, Georgia • Tucker, Georgia • New York, New York + 2 more
Conditions
Chronic Lymphocytic Leukemia, Hematopoietic and Lymphoid System Neoplasm, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Pain
Interventions
Methadone HCl Inject 10 mg/ml (will require dilution), Methadone
Drug
Lead sponsor
University of Utah
Other
Eligibility
29 Weeks to 48 Weeks
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
2
States / cities
Salt Lake City, Utah
Conditions
Healthy
Interventions
Recom Model 100, GE 5000 ECG Monitor System
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Tulsa, Oklahoma
Conditions
Myocardial Infarction, Angina, Unstable, Myocardial Ischemia, Coronary Disease
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
1,320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
San Francisco, California
Conditions
Death, Sudden, Cardiac, Ventricular Fibrillation, Tachycardia, Ventricular
Interventions
Defibrillation of pulseless VT/VF by AECD
Device
Lead sponsor
Foundation for Atlanta Veterans Education and Research, Inc.
Other
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Decatur, Georgia
Conditions
Syncope, Pre-syncope, Atrial Fibrillation, Supraventricular Tachycardia
Interventions
Standard Holter/Investigational patch
Device
Lead sponsor
Seattle Institute for Cardiac Research
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Chicago, Illinois • Enumclaw, Washington
Conditions
Phenylketonuria
Interventions
Preparative Radiation Therapy, Hepatocyte Transplant, Immunosuppression, Liver Evaluation, Neuro-psychological Assessment, Whole body Phe oxidation testing, Liver Biopsy
Radiation · Procedure · Drug + 3 more
Lead sponsor
Ira Fox
Other
Eligibility
14 Years to 55 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed No phase listed Observational Accepts healthy volunteers

Validating Dozee for Contactless Monitoring of Heart, Breathing, and Movemen

NCT07223931
Conditions
No Specific Medical Conditions or Disease States, No Specific Conditions
Interventions
Device: Telemetry monitoring
Device
Lead sponsor
Turtle Shell Technologies Pvt. Ltd.
Industry
Eligibility
18 Years to 100 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Midland, Texas
Conditions
Cystic Fibrosis
Interventions
Wearable device
Device
Lead sponsor
Byteflies
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Sickle Cell Disease
Interventions
Deferoxamine, Deferasirox, Deferiprone, Echocardiography, Electrocardiogram (ECG)
Drug · Device
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Fairfax, Virginia • Falls Church, Virginia
Conditions
Monitoring for Low Minute Ventilation Post Surgery
Interventions
Non-Invasive Respiratory Volume Monitor
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma
Interventions
Regadenoson 0.05mg, Regadensoson 0.1mg, Regadensoson 0.2mg, Regadensoson 0.4mg, Regadensoson 0.7mg, Regadensoson 1.0mg, Regadensoson 1.4mg
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Winston-Salem, North Carolina